Wolfe starts Stevanato with Outperform on return to growth

Wolfe Research initiated coverage of Stevanato Group (STVN) with an Outperform rating and $28 price target The company is poised to return to double-digit revenue growth as a supplier of key enabling components and solutions to biopharma, the analyst tells investors in a research note. The firm does not expect Stevanato’s growth to inflect, but believes it “is on the verge of turning the corner.” The company’s revenue growth should return to high-single digit levels over the course of 2025 and margins will improve via growth and mix, contends Wolfe.